Bayer to Invest $2.2 Billion in New U.S. Manufacturing Facility
Bayer has announced plans to invest approximately $2.2 billion in a new pharmaceutical manufacturing facility in New Albany, Ohio, marking a significant expansion of the company’s manufacturing footprint in the United States. The planned investment is part of Bayer’s long-term growth strategy and reflects the company’s continued focus on pharmaceutical innovation, advanced manufacturing capabilities and reliable access to medicines.
The Ohio project builds on more than $7 billion that Bayer has invested in pharmaceutical research and development and manufacturing in the United States over the past five years. The company views the U.S. as one of its most important pharmaceutical markets, as well as a major center for scientific research, innovation and advanced production.
Bayer said the new manufacturing site will strengthen its ability to produce innovative medicines for patients in the United States and international markets. The facility is planned as a flexible and modular campus capable of supporting both drug substance and drug product manufacturing.
“Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment,” said Bayer CEO Bill Anderson. “The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.”
The planned investment comes as pharmaceutical manufacturers continue to expand advanced production capabilities and seek greater resilience across their supply chains. Bayer’s new Ohio campus is expected to become an important component of the company’s global Product Supply network.
New Ohio Facility to Support Pharmaceutical Growth
The planned manufacturing campus will be located in the New Albany International Business Park in Ohio. Bayer expects the project to create approximately 600 high-value jobs once the facility is established. Construction of the site is also expected to support approximately 1,500 construction jobs, providing an economic boost during the development phase.
The campus is being designed with flexibility in mind, allowing Bayer to expand manufacturing capabilities as demand and production requirements evolve. The facility will combine drug substance and drug product manufacturing and incorporate advanced digital systems, automation and modern production technologies.
Initially, the manufacturing site is expected to support Bayer’s growing pharmaceutical portfolio in areas including oncology, cardiovascular disease and renal care. These therapeutic areas represent important parts of Bayer’s pharmaceutical business and include medicines intended to address significant health conditions.
The first module of the campus is planned to focus on drug substance manufacturing and is expected to become operational in 2031. Bayer plans to add a second module dedicated to drug product manufacturing, with operations currently targeted to begin in 2034.
The phased approach is designed to allow Bayer to develop the site progressively while aligning manufacturing capacity with the company’s pharmaceutical pipeline and future commercial needs.
Strengthening Bayer’s U.S. Manufacturing Network
The new Ohio facility will complement Bayer’s existing pharmaceutical operations across the United States. The company already maintains a network of major locations that support research, development, manufacturing and corporate activities.
Bayer’s U.S. pharmaceuticals headquarters is located in Whippany, New Jersey, while other important sites are located in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California.
The planned New Albany facility will add another strategically positioned manufacturing location to this network. Bayer expects the site to strengthen its ability to supply medicines while increasing resilience and reliability across its broader production system.
“The facility will be a strong strategic addition to our global Product Supply network. As we continue to invest in our existing manufacturing sites around the globe, our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability,” said Holger Weintritt, Head of Product Supply at Bayer’s Pharmaceuticals division.
The investment also demonstrates Bayer’s intention to maintain and expand its manufacturing capabilities in the United States while continuing to develop production facilities in other markets.
Focus on Advanced Manufacturing and Automation
A key feature of the planned Ohio campus will be its use of digital and automation technologies. Bayer intends to integrate modern manufacturing systems into the facility to support efficient, flexible and consistent pharmaceutical production.
The modular design could allow the company to adapt manufacturing operations as its portfolio develops. Rather than establishing a facility designed around a single production requirement, Bayer plans to create infrastructure capable of supporting different manufacturing needs over time.
Advanced manufacturing technologies are increasingly important to pharmaceutical companies as they seek to improve production efficiency, strengthen supply-chain reliability and maintain consistent quality standards. Bayer’s planned investment in Ohio is positioned within this broader industry trend.
The facility is also expected to bring together manufacturing expertise and a highly skilled workforce. The approximately 600 planned jobs are expected to include specialized positions associated with pharmaceutical manufacturing, engineering, technology and other technical functions.
Building a U.S. Pharmaceutical Innovation Ecosystem
Beyond manufacturing, Bayer said the Ohio site will form part of a broader U.S.-based collaboration ecosystem. The company plans to connect academic innovation with advanced pharmaceutical manufacturing expertise.
The objective is to create an environment in which research, technology development and production capabilities can work more closely together. Bayer believes stronger links between academic institutions and industry can contribute to the development of future-ready pharmaceutical manufacturing technologies.
Such collaboration could also support workforce development and provide opportunities for professionals with expertise in pharmaceutical sciences, engineering, automation, data and manufacturing technologies.
Sebastian Guth, Global Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer U.S., emphasized the importance of the U.S. market to the company’s pharmaceutical operations.
“The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond,” Guth said.
Long-Term Investment in U.S. Pharmaceutical Manufacturing
Bayer’s planned $2.2 billion investment represents another major step in the company’s broader U.S. pharmaceutical strategy. Combined with more than $7 billion in pharmaceutical R&D and manufacturing spending in the country over the past five years, the Ohio project highlights the company’s continued commitment to the U.S. market.
With construction expected to create approximately 1,500 jobs and the completed facility expected to support around 600 high-value positions, the project is also positioned to contribute to Ohio’s economic development.
The first manufacturing module is targeted for 2031, followed by the planned drug product manufacturing module in 2034. Once developed, the flexible campus is expected to complement Bayer’s existing U.S. network while supporting pharmaceutical production for both domestic and international markets.
Through the project, Bayer is combining investment in manufacturing infrastructure with digital technologies, workforce development and collaboration with the broader innovation community. The company expects the New Albany facility to become an important part of its long-term pharmaceutical supply network and its efforts to support the production and delivery of innovative medicines.
Source Link:https://www.bayer.com/
